论文部分内容阅读
目的探讨ｒＩＬ－２抗肿瘤机制。方法用“ＬＤＨ释放法”检测经不同处理的脾细胞对其敏感的靶细胞ＹＡＣ－１，不敏感的ｌｅｗｉｓ肺癌（ＬＬＣ）及耐受的ＬＬＣ肺转移细胞（ＬＬＣＦ１）体外杀伤功能。结果正常脾细胞对３种靶细胞的杀伤能力有明显差异（Ｐ＜０．０１）；经人ｒＩＬ－２体外激活后（ＬＡＫ细胞），杀瘤能力明显增强，并对ＬＬＣ、ＬＬＣＦ１细胞的杀伤作用已无明显差异；对ＬＬＣ血道转移也有明显抑制作用；激活时间对脾细胞杀瘤能力也有影响。结论人ｒＩＬ－２能激活小鼠脾细胞，使其杀瘤尤其是对具有抗ＮＫ细胞的肿瘤杀伤能力明显增强，对肿瘤转移也有疗效。
Objective To investigate the antitumor mechanism of rIL-2. Methods LDH release assay was used to detect the in vitro killing function of target cells YAC-1 sensitive to lewis lung cancer (LLC) and tolerant LLC lung metastatic cells (LLCF1). Results The killing ability of normal spleen cells to three kinds of target cells was significantly different (P<0.01). After in vitro activation of human rIL-2 (LAK cells), the tumorigenicity was significantly enhanced and the killing of LLC and LLCF1 cells was observed. The effect has no significant difference; it also has a significant inhibitory effect on the hematopoietic metastasis of LLC; the activation time also has an effect on the killing ability of spleen cells. Conclusions Human rIL-2 can activate mouse spleen cells, which makes tumor killing ability especially against tumor cells with anti-NK cells significantly enhanced. It is also effective for tumor metastasis.